EDWARD L TOBINICK
Medical Practice at Ocean Blvd, Boca Raton, FL
License number
Florida 108017
Issued Date
Aug 17, 2010
Effective Date
Aug 17, 2010
Expiration Date
Jan 31, 2019
Category
Health Care
Type
Medical Doctor
Address
Address
4101 N Ocean Blvd APT 1707, Boca Raton, FL 33431
Phone
(561) 353-3970
Personal information
See more information about EDWARD L TOBINICK at radaris.comName
Address
Phone
2901 Ocean Pl, Boca Raton, FL 33487
Organization information
See more information about EDWARD L TOBINICK at bizstanding.comEdward L Tobinick MD
2300 Glades Rd, Boca Raton, FL 33431
Categories:
Attorneys, Dermatology Physicians & Surgeons, Insurance Law Attorneys, ...
Phone:
(561) 353-9707 (Phone)
Professional information
See more information about EDWARD L TOBINICK at trustoria.com
Cytokine Antagonists For Neurological And Neuropsychiatric Disorders
Cytokine Antagonists For Neurological And Neuropsychiatric Disorders
US Patent:
2013011, May 9, 2013
Filed:
Jan 2, 2013
Appl. No.:
13/732892
Inventors:
Edward L. Tobinick - Boca Raton FL, US
International Classification:
A61K 39/395
US Classification:
4241341, 4241451, 4241421, 4241331
Abstract:
A method, comprising: introducing a therapeutically effective amount of a specific TNF blocker to cerebrospinal fluid of a human in need of treatment for symptoms associated with neronal compression.
Methods For Treatment Of Brain Injury Utilizing Biologics
Methods For Treatment Of Brain Injury Utilizing Biologics
US Patent:
2013022, Aug 29, 2013
Filed:
Oct 31, 2011
Appl. No.:
13/848044
Inventors:
Edward Lewis Tobinick - Boca Raton FL, US
Assignee:
TACT IP LLC - Boca Raton FL
International Classification:
A61K 39/395
US Classification:
4241341
Abstract:
A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs, chimeric TNF mAbs, domain TNF antibodies, mAB fragments, anti-TNF nanobodies, dominant negative TNF constructs and TNF inhibitory single chain antibody fragments. One of the preferred embodiments of this invention is the perispinal administration of etanercept for treatment of mammals following stroke. The use of Trendelenburg positioning, catheters, pumps, or depot formulations are included.